Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pharma provides orlistat intermediates
Show results for
Products

Companies


Refine by
Date

  • Older

Pharma Provides Orlistat Intermediates Articles & Analysis: Older

11 news found

Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

Alfa Chemistry is one of the leading chemical manufacturers and suppliers who has been able to maintain its leadership position in the pharmaceutical sector by offering a broad product portfolio that caters to all aspects of the drug creation process. Always innovative and outstanding, Alfa Chemistry now has an extensive range of products within the pharmaceutical field, including PROTAC building ...

ByAlfa Chemistry


Protheragen-ING Announces Lyophilized Flash-release Formulations Development Capabilities

Protheragen-ING Announces Lyophilized Flash-release Formulations Development Capabilities

Protheragen-ING has recently announced its ability to provide freeze-drying flash-release formulation development services to clients involved in drug discovery and development worldwide. Lyophilized flash-release formulations are advanced drug delivery systems that incorporate the benefits of both lyophilization and flash-release technologies. “Whether customers are trying to develop a ...

ByProtheragen-ING


Huateng Pharma Strengthens Global CDMO Capabilities Across Key Sectors

Huateng Pharma Strengthens Global CDMO Capabilities Across Key Sectors

Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce its comprehensive range of services catering to Veterinary APIs, Pharmaceutical Intermediates, Cosmetic Ingredients, and Specialty & Fine Chemicals. With a steadfast commitment to innovation, quality, and customer satisfaction, Huateng Pharma continues to make significant strides in the ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Huateng Pharmace to Showcase Innovations at CPHI China 2024

Huateng Pharmace to Showcase Innovations at CPHI China 2024

Shanghai, China – June 14, 2024 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services for Active Pharmaceutical Ingredients (APIs) and intermediates, is excited to announce its participation in CPHI China 2024. The event will take place from June 19 to 21, 2024, at the Shanghai New ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Huateng Pharma Proudly Unveils Its New Product - Semaglutide Side Chains

Huateng Pharma Proudly Unveils Its New Product - Semaglutide Side Chains

Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Huateng Pharma's Featured Product Line: Veterinary API and Intermediates

Huateng Pharma's Featured Product Line: Veterinary API and Intermediates

Huateng Pharma, a Contract Development and Manufacturing Organization (CDMO) specializing in APIs and intermediates, is proud to announce its featured product line catering specifically to the veterinary industry. With a commitment to delivering high-quality solutions, Huateng Pharma offers a comprehensive range of veterinary APIs and intermediates, including Fluralaner (CAS NO.: 864731-61-3) and ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Huateng Pharma Introduces Anti-Diabetes Intermediates

Huateng Pharma Introduces Anti-Diabetes Intermediates

Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. Emphasizing the potential impact on diabetes drug development, Huateng Pharma's Research and Development Director expressed enthusiasm, stating, "Our new line of anti-diabetes intermediates represents a ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Huateng Pharma Launches Exciting New Product Line - Fexuprazan and Vonoprazan Intermediates

Huateng Pharma Launches Exciting New Product Line - Fexuprazan and Vonoprazan Intermediates

Huateng Pharma, a leading innovator in pharmaceutical intermediates, is proud to announce the introduction of its latest product line - Gastrointestinal API Intermediates, featuring the groundbreaking compounds Fexuprazan and Vonoprazan Intermediates. These cutting-edge substances have been meticulously developed to meet the growing demands of the pharmaceutical industry. Fexuprazan Intermediates ...

ByHunan Huateng Pharmaceutical Co. Ltd.


BOC Sciences Fermentation CDMO Services Prompt a New Era for Pharmaceutical Compound Production   

BOC Sciences Fermentation CDMO Services Prompt a New Era for Pharmaceutical Compound Production  

BOC Sciences has placed great emphasis on microbial fermentation techniques for years. Its comprehensive fermentation CDMO services and small microbial molecules have delivered tremendous value to the pharmaceutical industry. And the future looks even better. Pharmaceutical enterprises have been confronted with numerous challenges, such as rising cost pressures and uncertainty in the upstream ...

ByBOC Sciences


Huateng Pharma Provides Orlistat Intermediates CAS NO 104801-96-9 Large Scale Services

Huateng Pharma Provides Orlistat Intermediates CAS NO 104801-96-9 Large Scale Services

Orlistat is a drug designed to treat obesity. The main function of Orlistat is to prevent the absorption of fat from the diet in humans. ...

ByHunan Huateng Pharmaceutical Co. Ltd.


CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan`s Top Pharmaceutical Companies

CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan`s Top Pharmaceutical Companies

TOKYO and TEL AVIV, Israel, Sept. 30, 2021 /PRNewswire/ -- CytoReason, an AI company developing computational disease models for discovery and clinical drug development, and Summit Pharmaceuticals International (SPI), a Japanese company providing service and products to the pharmaceutical industry (wholly-owned subsidiary of Sumitomo Corporation), today announced that CytoReason has entered the ...

ByCytoReason

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT